Goel Ashish, Nayak Vikash
Jaypee Hospital, Sector 128, Noida, India.
Indian J Surg Oncol. 2020 Dec;11(4):668-673. doi: 10.1007/s13193-020-01230-3. Epub 2020 Sep 25.
Multimodality treatment with neoadjuvant chemoradiation followed by surgery has become the standard of care for esophageal cancer. In the recent years, there has been a shift in focus of surgical approach from open esophagectomy to minimally invasive esophagectomy. Robot-assisted esophagectomy is being performed more often in centers across the world. However, there is limited data on role of robot-assisted esophagectomy in patients who have received neoadjuvant chemoradiation. Initial reports have shown that integrating neoadjuvant therapy to robot-assisted esophagectomy is feasible and safe. With the growing popularity of robot-assisted surgery worldwide among both surgeons and patients, understanding the impact of neoadjuvant chemoradiation on the procedure and its oncological outcome seems worthwhile. In the present study, we present a review of available literature on the feasibility and safety of robot-assisted minimally invasive esophagectomy in esophageal cancer patients after neoadjuvant chemoradiation.
新辅助放化疗后行手术的多模式治疗已成为食管癌的标准治疗方案。近年来,手术方式的重点已从开放食管切除术转向微创食管切除术。机器人辅助食管切除术在世界各地的医疗中心越来越多地开展。然而,关于机器人辅助食管切除术在接受新辅助放化疗患者中的作用的数据有限。初步报告表明,将新辅助治疗与机器人辅助食管切除术相结合是可行且安全的。随着机器人辅助手术在全球范围内受到外科医生和患者的日益欢迎,了解新辅助放化疗对手术及其肿瘤学结局的影响似乎很有价值。在本研究中,我们对新辅助放化疗后食管癌患者行机器人辅助微创食管切除术的可行性和安全性的现有文献进行综述。